Quantcast

Latest Lipid storage disorders Stories

2014-08-18 12:26:52

DUBLIN, Aug. 18, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Lysosomal Storage Diseases Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnvar/20130307/600769 The term lysosomal storage diseases refers to a group of rare inherited disorders caused by the deficiency of lysosomal enzymes, activator proteins, proteins required for normal post-translational modification of lysosomal enzymes or proteins required for intracellular...

2014-08-11 20:24:21

LONDON, Aug. 11, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Lysosomal Storage Disorder-Pipeline Insights, 2014https://www.reportbuyer.com/product/2278642/-Lysosomal-Storage-Disorder-Pipeline-Insights-2014.htmlSUMMARYDelveInsight's," Lysosomal Storage Disorder-Pipeline Insights, 2014", report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline...

2014-08-09 23:04:05

Emily Gimble's new single, “Mighty Like a Rose,” is available for download through many online music distributors. Austin, Texas (PRWEB) August 09, 2014 Pianist, vocalist and newest member of Asleep at the Wheel, Emily Gimble has a brand new single, “Mighty Like a Rose,” currently available for downloads on the web at CD Baby.com, iTunes, Amazon and other online distributors. All proceeds benefit Beyond Batten Disease Foundation (BBDF), a nonprofit organization established to...

2014-07-30 16:29:33

LEXINGTON, Mass., July 30, 2014 /PRNewswire/ -- Synageva BioPharma Corp. ("Synageva") (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, today reported second quarter 2014 financial results, and provided other business updates. Second Quarter 2014 Financial Results For the quarter ended June 30, 2014, Synageva reported a net loss of $50.2 million compared to a net loss of $22.1 million for the corresponding quarter of the prior year....

2014-07-27 23:01:10

LifeScienceIndustryResearch.com adds “Metachromatic Leukodystrophy (MLD) Global Clinical Trials Review, H2, 2014” to its store. This report provides elemental information and data relating to the clinical trials on MLD. Dallas, TX (PRWEB) July 27, 2014 Metachromatic leukodystrophy (MLD, also called Arylsulfatase A deficiency) is a lysosomal storage disease which is commonly listed in the family of leukodystrophies as well as among the sphingolipidoses as it affects the metabolism of...

2014-07-23 23:18:14

Investment builds company strength in preparation for clinical trials. Alachua, Fla. (PRWEB) July 22, 2014 CTD Holdings, Inc. (OTCQB:CTDH), a manufacturer and distributor of cyclodextrins for the pharmaceutical, medical device, cosmetics, and other markets, announced today that it has closed on a Private Placement with a group of qualified private investors led by Novit L.P., an investment arm of U.S. Pharmacia. The transaction involved the signing of a Securities Purchase Agreement...

2014-07-22 08:32:03

- Neurotrope enters into world-wide, exclusive license agreement with Mount Sinai; Files related provisional patent for Bryostatin-1 - PLANTATION, Fla., July 22, 2014 /PRNewswire/ -- Neurotrope Bioscience, Inc., a subsidiary of Neurotrope, Inc. (OTCQB: NTRP) has signed a world-wide, exclusive license agreement with the Icahn School of Medicine at Mount Sinai (Mount Sinai) to utilize its proprietary information and data package for the use of Bryostatin-1 in the treatment of...

2014-07-09 23:04:12

Dr. Jeffrey Tate promoted to CEO; C.E. Rick Strattan to serve as Executive Chairman. Alachua, FL (PRWEB) July 09, 2014 CTD Holdings, Inc. (OTCQB:CTDH), a distributor and manufacturer of cyclodextrin products including the orphan drug designated Trappsol(R) Cyclo(TM), today announced the promotion of Dr. Jeffrey Tate to Chief Executive Officer, following the retirement of C.E. Rick Strattan. Dr. Tate will hold the titles of President and CEO of CTD Holdings, Inc.; Mr. Strattan will become...

2014-06-30 16:26:45

Phase 3 Study Meets Primary Endpoint and Six Secondary Endpoints Across Multiple Disease-Related Abnormalities LEXINGTON, Mass., June 30, 2014 /PRNewswire/ -- Synageva BioPharma Corp. (Synageva) (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare diseases, announced today that the global, randomized, double-blind, placebo-controlled Phase 3 ARISE trial of sebelipase alfa in 66 children and adults with lysosomal acid lipase deficiency (LAL...

2014-06-03 08:31:40

LEXINGTON, Mass., June 3, 2014 /PRNewswire/ -- Synageva BioPharma Corp. (Synageva) (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare diseases, today announced data presentations and a company-sponsored satellite symposium at the European Atherosclerosis Society (EAS) Congress being held May 31-June 3, 2014 in Madrid, Spain. Logo - http://photos.prnewswire.com/prnh/20140522/90728 Sebelipase alfa continues to improve disease-related abnormalities...


Word of the Day
kenspeckle
  • Having so marked an appearance as easily to be recognized.
This word may come from the Swedish 'kanspak,' quick at recognizing persons or things, or else from confusion with 'conspicuous.'